Proteomic identification of saeRS-dependent targets critical for protective humoral immunity against Staphylococcus aureus skin infection

Infection and Immunity

Volumn 83, Issue 9, 2015, Pages 3712-3721

  Zhao, Fan ^a   Cheng, Brian L ^a   Boyle Vavra, Susan ^a   Alegre, Maria Luisa ^a   Daum, Robert S ^a   Chong, Anita S ^a   Montgomery, Christopher P ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HEMOLYSIN; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; POLYCLONAL ANTIBODY; SAERS PROTEIN; UNCLASSIFIED DRUG; PROTEIN KINASE; SAER PROTEIN, STAPHYLOCOCCUS AUREUS; SAES PROTEIN, STAPHYLOCOCCUS AUREUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; CONTROLLED STUDY; DELETION MUTANT; FEMALE; HOST PATHOGEN INTERACTION; HUMORAL IMMUNITY; MOUSE; NONHUMAN; OPERON; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RECURRENT INFECTION; SECONDARY INFECTION; STAPHYLOCOCCUS INFECTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASES; PROTEOMICS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84939540640     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00667-15     Document Type: Article

References (47)

1. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666-674. http://dx.doi.org/10.1056/NEJMoa055356.
2. McCaig LF, McDonald LC, Mandal S, Jernigan DB. 2006. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 12:1715-1723. http://dx.doi.org/10.3201/eid1211.060190.
3. Daum RS, Spellberg B. 2012. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 54:560-567. http://dx.doi.org/10.1093/cid/cir828.
4. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan IS, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A. 2013. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 309:1368-1378. http://dx.doi.org/10.1001/jama.2013.3010.
5. Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339:520-532. http://dx.doi.org/10.1056/NEJM199808203390806.
6. Atkins KL, Burman JD, Chamberlain ES, Cooper JE, Poutrel B, Bagby S, Jenkins AT, Feil EJ, van den Elsen JM. 2008. S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. Mol Immunol 45:1600-1611. http://dx.doi.org/10.1016/j.molimm.2007.10.021.
7. Fleischer B, Schrezenmeier H. 1988. T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med 167:1697-1707.
8. Zipfel PF, Skerka C. 2014. Staphylococcus aureus: the multi headed hydra resists and controls human complement response in multiple ways. Int J Med Microbiol 304:188-194. http://dx.doi.org/10.1016/j.ijmm.2013.11.004.
9. Löffler B, Hussain M, Grundmeier M, Bruck M, Holzinger D, Varga G, Roth J, Kahl BC, Proctor RA, Peters G. 2010. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog 6:e1000715. http://dx.doi.org/10.1371/journal.ppat.1000715.
10. Reyes-Robles T, Alonzo F, III, Kozhaya L, Lacy DB, Unutmaz D, Torres VJ. 2013. Staphylococcus aureus leukotoxin ED targets the chemokine receptors CXCR1 and CXCR2 to kill leukocytes and promote infec-tion. Cell Host Microbe 14:453-459. http://dx.doi.org/10.1016/j.chom.2013.09.005.
11. Cheung AL, Bayer AS, Zhang G, Gresham H, Xiong YQ. 2004. Regulation of virulence determinants in vitro and in vivo in Staphylococcus aureus. FEMS Immunol Med Microbiol 40:1-9. http://dx.doi.org/10.1016/S0928-8244(03)00309-2.
12. Adhikari RP, Novick RP. 2008. Regulatory organization of the staphylococcal sae locus. Microbiology 154:949-959. http://dx.doi.org/10.1099/mic.0.2007/012245-0.
13. Nygaard TK, Pallister KB, Ruzevich P, Griffith S, Vuong C, Voyich JM. 2010. SaeR binds a consensus sequence within virulence gene promoters to advance USA300 pathogenesis. J Infect Dis 201:241-254. http://dx.doi.org/10.1086/649570.
14. Montgomery CP, Boyle-Vavra S, Daum RS. 2010. Importance of the global regulators Agr and SaeRS in the pathogenesis of CA-MRSA USA300 infection. PLoS One 5:e15177. http://dx.doi.org/10.1371/journal.pone.0015177.
15. Montgomery CP, Daniels M, Zhao F, Alegre ML, Chong AS, Daum RS. 2014. Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A. Infect Immun 82:2125-2134. http://dx.doi.org/10.1128/IAI.01491-14.
16. Charpentier E, Anton AI, Barry P, Alfonso B, Fang Y, Novick RP. 2004. Novel cassette-based shuttle vector system for Gram-positive bacteria. Appl Environ Microbiol 70:6076-6085. http://dx.doi.org/10.1128/AEM.70.10.6076-6085.2004.
17. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. 2007. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 13:1405-1406. http://dx.doi.org/10.1038/nm1207-1405.
18. Burnside K, Lembo A, Harrell MI, Klein JA, Lopez-Guisa J, Siegesmund AM, Torgerson TR, Oukka M, Molina DM, Rajagopal L. 2012. Vaccination with a UV-irradiated genetically attenuated mutant of Staphylococcus aureus provides protection against subsequent systemic infection. J Infect Dis 206:1734-1744. http://dx.doi.org/10.1093/infdis/jis579.
19. Barbour AG, Jasinskas A, Kayala MA, Davies DH, Steere AC, Baldi P, Felgner PL. 2008. A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi. Infect Immun 76:3374-3389. http://dx.doi.org/10.1128/IAI.00048-08.
20. Davies DH, Liang X, Hernandez JE, Randall A, Hirst S, Mu Y, Romero KM, Nguyen TT, Kalantari-Dehaghi M, Crotty S, Baldi P, Villarreal LP, Felgner PL. 2005. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A 102:547-552. http://dx.doi.org/10.1073/pnas.0408782102.
21. Davies DH, Molina DM, Wrammert J, Miller J, Hirst S, Mu Y, Pablo J, Unal B, Nakajima-Sasaki R, Liang X, Crotty S, Karem KL, Damon IK, Ahmed R, Villarreal L, Felgner PL. 2007. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 7:1678-1686. http://dx.doi.org/10.1002/pmic.200600926.
22. Prabhakara R, Foreman O, De Pascalis R, Lee GM, Plaut RD, Kim SY, Stibitz S, Elkins KL, Merkel TJ. 2013. Epicutaneous model of community-acquired Staphylococcus aureus skin infections. Infect Immun 81:1306-1315. http://dx.doi.org/10.1128/IAI.01304-12.
23. Sampedro GR, DeDent AC, Becker RE, Berube BJ, Gebhardt MJ, Cao H, Bubeck Wardenburg J. 2014. Targeting Staphylococcus aureus alphatoxin as a novel approach to reduce severity of recurrent skin and softt-issue infections. J Infect Dis 210:1012-1018. http://dx.doi.org/10.1093/infdis/jiu223.
24. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alphahemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202:1050-1058. http://dx.doi.org/10.1086/656043.
25. Wilke GA, Bubeck Wardenburg J. 2010. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc Natl Acad Sci U S A 107:13473-13478. http://dx.doi.org/10.1073/pnas.1001815107.
26. Spaan AN, Henry T, van Rooijen WJ, Perret M, Badiou C, Aerts PC, Kemmink J, de Haas CJ, van Kessel KP, Vandenesch F, Lina G, van Strijp JA. 2013. The staphylococcal toxin Panton-Valentine leukocidin targets human C5a receptors. Cell Host Microbe 13:584-594. http://dx.doi.org/10.1016/j.chom.2013.04.006.
27. Smith EJ, Visai L, Kerrigan SW, Speziale P, Foster TJ. 2011. The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus. Infect Immun 79:3801-3809. http://dx.doi.org/10.1128/IAI.05075-11.
28. Alonzo F, III, Kozhaya L, Rawlings SA, Reyes-Robles T, DuMont AL, Myszka DG, Landau NR, Unutmaz D, Torres VJ. 2013. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 493:51-55.
29. Foster TJ, Hook M. 1998. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 6:484-488. http://dx.doi.org/10.1016/S0966-842X(98)01400-0.
30. Fitzgerald JR, Loughman A, Keane F, Brennan M, Knobel M, Higgins J, Visai L, Speziale P, Cox D, Foster TJ. 2006. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor. Mol Microbiol 59:212-230. http://dx.doi.org/10.1111/j.1365-2958.2005.04922.x.
31. Zurek OW, Nygaard TK, Watkins RL, Pallister KB, Torres VJ, Horswill AR, Voyich JM. 2014. The role of innate immunity in promoting SaeR/ S-mediated virulence in Staphylococcus aureus. J Innate Immun 6:21-30. http://dx.doi.org/10.1159/000351200.
32. Verkaik NJ, Lebon A, de Vogel CP, Hooijkaas H, Verbrugh HA, Jaddoe VW, Hofman A, Moll HA, van Belkum A, van Wamel WJ. 2010. Induction of antibodies by Staphylococcus aureus nasal colonization in young children. Clin Microbiol Infect 16:1312-1317. http://dx.doi.org/10.1111/j.1469-0691.2009.03073.x.
33. den Reijer PM, Lemmens-den Toom N, Kant S, Snijders SV, Boelens H, Tavakol M, Verkaik NJ, van Belkum A, Verbrugh HA, van Wamel WJ. 2013. Characterization of the humoral immune response during Staphylococcus aureus bacteremia and global gene expression by Staphylococcus aureus in human blood. PLoS One 8:e53391. http://dx.doi.org/10.1371/journal.pone.0053391.
34. Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, Johnson JK, Nguyen C, Chen WH, Roghmann MC. 2012. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis 206:915-923. http://dx.doi.org/10.1093/infdis/jis462.
35. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. 2013. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 56:1554-1561. http://dx.doi.org/10.1093/cid/cit123.
36. Hermos CR, Yoong P, Pier GB. 2010. High levels of antibody to Panton-Valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin Infect Dis 51:1138-1146. http://dx.doi.org/10.1086/656742.
37. Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, Anderson AS, Donald RG. 2012. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol 19:1641-1650. http://dx.doi.org/10.1128/CVI.00354-12.
38. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205:287-294. http://dx.doi.org/10.1084/jem.20072208.
39. Mocca CP, Brady RA, Burns DL. 2014. Role of antibodies in protection elicited by active vaccination with genetically inactivated alpha hemolysin in a mouse model of Staphylococcus aureus skin and soft tissue infections. Clin Vaccine Immunol 21:622-627. http://dx.doi.org/10.1128/CVI.00051-14.
40. Brown EL, Dumitrescu O, Thomas D, Badiou C, Koers EM, Choudhury P, Vazquez V, Etienne J, Lina G, Vandenesch F, Bowden MG. 2009. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect 15:156-164. http://dx.doi.org/10.1111/j.1469-0691.2008.02648.x.
41. Karauzum H, Adhikari RP, Sarwar J, Devi VS, Abaandou L, Haudenschild C, Mahmoudieh M, Boroun AR, Vu H, Nguyen T, Warfield KL, Shulenin S, Aman MJ. 2013. Structurally designed attenuated subunit vaccines for S. aureus LukS-PV and LukF-PV confer protection in a mouse bacteremia model. PLoS One 8:e65384. http://dx.doi.org/10.1371/journal.pone.0065384.
42. Schennings T, Farnebo F, Szekely L, Flock JI. 2012. Protective immu-nization against Staphylococcus aureus infection in a novel experimental wound model in mice. APMIS 120:786-793. http://dx.doi.org/10.1111/j.1600-0463.2012.02907.x.
43. Rauch S, Gough P, Kim HK, Schneewind O, Missiakas D. 2014. Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infection. Infect Immun 82:4889-4898. http://dx.doi.org/10.1128/IAI.02328-14.
44. Spaulding AR, Lin YC, Merriman JA, Brosnahan AJ, Peterson ML, Schlievert PM. 2012. Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses. Vaccine 30:5099-5109. http://dx.doi.org/10.1016/j.vaccine.2012.05.067.
45. Montgomery CP, Boyle-Vavra S, Adem PV, Lee JC, Husain AN, Clasen J, Daum RS. 2008. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis 198:561-570. http://dx.doi.org/10.1086/590157.
46. Boyle-Vavra S, Li X, Alam MT, Read TD, Sieth J, Cywes-Bentley C, Dobbins G, David MZ, Kumar N, Eells SJ, Miller LG, Boxrud DJ, Chambers HF, Lynfield R, Lee JC, Daum RS. 2015. USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus. mBio 6(2): e02585.
47. David MZ, Daum RS. 2010. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 23:616-687. http://dx.doi.org/10.1128/CMR.00081-09.